Insider Selling: uniQure (NASDAQ:QURE) CEO Sells 6,696 Shares of Stock

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 6,696 shares of uniQure stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $50.00, for a total value of $334,800.00. Following the completion of the transaction, the chief executive officer owned 519,227 shares in the company, valued at $25,961,350. This represents a 1.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Stock Down 3.2%

Shares of NASDAQ QURE traded down $1.59 during mid-day trading on Friday, reaching $47.51. 3,154,443 shares of the company were exchanged, compared to its average volume of 2,765,936. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. The stock has a market cap of $3.00 billion, a price-to-earnings ratio of -13.65 and a beta of 0.98. uniQure N.V. has a 1 year low of $8.73 and a 1 year high of $71.50. The firm has a 50-day moving average of $27.23 and a 200 day moving average of $22.85.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The company had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. On average, research analysts expect that uniQure N.V. will post -3.64 earnings per share for the current year.

Institutional Investors Weigh In On uniQure

Large investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. raised its stake in uniQure by 5.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after acquiring an additional 533 shares during the last quarter. Arizona State Retirement System grew its stake in uniQure by 6.0% during the 4th quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock valued at $267,000 after purchasing an additional 627 shares during the last quarter. Ensign Peak Advisors Inc increased its holdings in shares of uniQure by 21.7% in the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock valued at $87,000 after purchasing an additional 650 shares during the period. FNY Investment Advisers LLC increased its holdings in shares of uniQure by 76.7% in the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 718 shares during the period. Finally, CIBC Private Wealth Group LLC purchased a new position in shares of uniQure in the third quarter worth about $50,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

QURE has been the subject of several recent analyst reports. Mizuho boosted their price objective on shares of uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a research note on Thursday. Chardan Capital raised their target price on shares of uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. HC Wainwright reaffirmed a “buy” rating on shares of uniQure in a research report on Thursday, June 18th. Royal Bank Of Canada upped their target price on uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a research report on Thursday, June 18th. Finally, Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Twelve research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, uniQure has an average rating of “Moderate Buy” and a consensus target price of $61.67.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.